Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jul:201:152-158.
doi: 10.1016/j.urology.2025.04.056. Epub 2025 May 29.

GLP-1 Agonist Use Among Men With Localized Prostate Cancer: A Narrative Review and Rationale for Prospective Clinical Trials

Andrew Fang  1 , Daniel E Frigo  1 , Andrew Hahn  1 , Zayd Razouki  1 , Jessica Hwang  1 , Efstratios Koutroumpakis  1 , Tarek Lawen  1 , Matthew Smith  1 , Jill Hamilton-Reeves  2 , John DiGiovanni  3 , Noel Higgason  1 , Rebekka S Garcia  1 , Brian F Chapin  1 , Curtis Pettaway  1 , Lisly Chery  1 , Patricia Troncoso  1 , Christopher Logothetis  1 , Carrie R Daniel  1 , Peng Wei  1 , Justin R Gregg  4
Affiliations
Review

GLP-1 Agonist Use Among Men With Localized Prostate Cancer: A Narrative Review and Rationale for Prospective Clinical Trials

Andrew Fang et al. Urology. 2025 Jul.

Abstract

Glucagon-like peptide 1 (GLP-1) receptor agonists are a revolutionary treatment for obesity, and investigations into other uses of these agents are ongoing. Epidemiologic data suggest that prostate cancer risk may decrease following GLP-1 receptor agonist initiation. To better define the potential role of GLP-1 receptor agonist use among men with prostate cancer, we will define changes that occur in men with prostate cancer following lifestyle intervention; illuminate the current relationship between these interventions and prostate cancer risk; and explore the potential mechanism of action on tumor biology, providing rationale for evaluating its effects on prostate cancer in a planned clinical trial.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest JRG is a consultant for Bayer and J&J. DEF has received research funding from GTx, Inc, and has a familial relationship with March Biosciences, Biocity Biopharmaceuticals, Hummingbird Bioscience, Bellicum Pharmaceuticals, Maia Biotechnology, Alms Therapeutics, Hinova Pharmaceuticals, and Barricade Therapeutics. AWH reports advisory board consulting to Janssen, Intellisphere, AVEO, Exelixis, Eisai, and Pfizer; honorarium from Medscape, Binaytara Foundation, and Projects in Knowledge; and institutional research funding from Bayer and Eisai.

Substances

LinkOut - more resources